Eloxx Pharmaceuticals, Inc.’s (NASDAQ:ELOX) Quiet Period To End Tomorrow

Eloxx Pharmaceuticals’ (NASDAQ:ELOX) quiet period will end on Monday, July 20th. Eloxx Pharmaceuticals had issued 2,975,000 shares in its public offering on June 9th. The total size of the offering was $32,725,000 based on an initial share price of $11.00. During Eloxx Pharmaceuticals’ quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Eloxx Pharmaceuticals Stock Performance

ELOX stock opened at $12.00 on Friday. Eloxx Pharmaceuticals has a twelve month low of $11.13 and a twelve month high of $17.50. The stock has a market capitalization of $8.28 million, a price-to-earnings ratio of -0.78 and a beta of -1,891.27. The stock has a fifty day simple moving average of $17.53.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.